Changes in levels of serum CEA and its clinical significance in patients with non-small-cell lung cancer treated with gefitinib
WEI Wei
ZHANG Jie-xia
LAN Yu-hong
LI Yong-sheng
ZHONG Biao
LI Pei-jian
BAI Li
Abstract：Objective To observe the changes in levels of serum carcinoembryonic antigen ( CEA) in patients before and after gefitinib treatment of non-small-cell lung cancer ( NSCLC) and to investigate the clinical significance .Methods Forty patients with NSCLC in clinical stage of Ⅲ~Ⅳwere treated with gefitinib and radiotherapy , and we stopped if the tumor progression or toxicity reaction were found in patients .After treatment , all patients were divided into the control group and non-control group according to RECIST1.1 (Response Evaluation Criteria in Solid Tumors in 2009).The periph-eral blood was collected in the morning to detect the serum CEA by electro-chemiluminescence immunoassay ( ECLIA ) . Before treatment , the patients were divided into the high CEA group ( CEA>30 μg/L) and low CEA group ( CEA ≤30μg/L) .Two groups were followed up to December , 2012 .The adverse reactions and progression free survival ( PFS) were recorded .Results There was no difference in CEA levels before treatment between the control group and non -control group(P>0.05),but the levels of CEA in the control group decreased more after treatment than that of the non -control group (all P<0.01).No difference was found in the adverse reaction between the high CEA group and the low CEA group (P>0.05), but the PFS at 9 months and 12 months was higher in the high CEA group than that in the low CEA group (P<0.01).Conclusion The serum CEA level is decreased in NSCLC patients after treatment of gefitinib , which can be-come the biological marker in predicting the efficacy and prognosis .
Keywords：carcinomanon-small-cell lunggefitinibcarcinoembryonic antigen
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 1-3 )